Yidu Tech

The company's core offering is its proprietary "AI Medical Brain," YiduCore, an intelligent platform that processes and analyzes vast amounts of authorized medical data. YiduCore is designed to convert unstructured and fragmented data from hospital IT systems into standardized, research-grade datasets. This platform underpins the company's three main business segments: Big Data Platform and Solutions, Life Sciences Solutions, and Health Management Platform and Solutions. Revenue is generated through providing these data intelligence platforms, analytics-driven solutions, and related operational services on a subscription or project basis to a diverse client base.

Yidu Tech serves a wide array of participants in the healthcare value chain, including hospitals, pharmaceutical and biotech companies, research institutions, and regulators. For hospitals, the platform assists in improving clinical decision-making and operational efficiency. For life sciences companies, it provides real-world evidence and data-driven insights to accelerate clinical trials and drug development, which represents a significant and growing revenue stream. A major milestone was its Initial Public Offering (IPO) on the Hong Kong Stock Exchange on January 15, 2021, which raised approximately HK$4.1 billion and attracted cornerstone investors such as Tencent and the Canada Pension Plan Investment Board. For the fiscal year 2024, the company reported total revenue of RMB 807.1 million and an improved gross profit margin of 42.1%.